← Back to Search

Immunotherapy

Patients with SF3B1, U2AF1 or SRSF2 mutation for Mutations (PRISMM Trial)

N/A
Waitlist Available
Led By Cesar Santa-Maria, MD
Research Sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights
No Placebo-Only Group

Summary

This study is being done to see if patients with metastatic solid tumors (hematologic malignancies and lymphoma excluded) who have a specific genetic mutation in patients' tumor (the SF3B1, U2AF1 or SRSF2 mutation), are more likely to respond to immunotherapy agents that are now commercially available.

Eligible Conditions
  • Gene Mutation
  • Mutations
  • Metastatic Tumor

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Feasibility of case review as assessed by time to issuance of recommendations
Feasibility of study as assessed by completion of study accrual within study time frame
Feasibility of study as assessed by physician responses

Side effects data

From 2023 Phase 3 trial • 1460 Patients • NCT04145219
58%
Oral pruritus
55%
Throat irritation
33%
Ear pruritus
33%
Abdominal pain upper
25%
Nasopharyngitis
21%
Lip swelling
20%
Glossodynia
19%
Nausea
17%
Taste disorder
14%
Mouth swelling
14%
Swollen tongue
13%
Diarrhoea
13%
Mouth ulceration
9%
Pharyngeal swelling
7%
Tongue ulceration
7%
Vomiting
6%
Tooth loss
5%
Pharyngitis
5%
Bronchitis
5%
COVID-19
3%
Upper respiratory tract infection
2%
Asthma
100%
80%
60%
40%
20%
0%
Study treatment Arm
HDM SLIT-tablet (12 SQ-HDM)
Placebo SLIT-tablet

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Patients with SF3B1, U2AF1 or SRSF2 mutationExperimental Treatment1 Intervention
Metastatic solid tumor patients that have a SF3B1, U2AF1 or SRSF2 mutation

Find a Location

Who is running the clinical trial?

Avon Breast Health Access FundUNKNOWN
Vanderbilt UniversityOTHER
710 Previous Clinical Trials
6,143,862 Total Patients Enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsLead Sponsor
569 Previous Clinical Trials
33,362 Total Patients Enrolled
~1 spots leftby Aug 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top